OPTIMIZATION OF PEPTABODIES ANTI-EGF RECEPTOR: A NEW POTENTIAL DRUG FOR CANCER THERAPIES.

• Unité de recherche: INNOSUISSE
• Numéro de projet: 7295.3;4 LSPP-LS
• Titre du projet anglais: OPTIMIZATION OF PEPTABODIES ANTI-EGF RECEPTOR: A NEW POTENTIAL DRUG FOR CANCER THERAPIES.

Description succincte (Anglais)

OPTIMIZATION OF PEPTABODIES ANTI-EGF RECEPTOR: A NEW POTENTIAL DRUG FOR CANCER THERAPIES.

Description succincte (Français)

OPTIMIZATION OF PEPTABODIES ANTI-EGF RECEPTOR: A NEW POTENTIAL DRUG FOR CANCER THERAPIES.

Résumé des résultats (Abstract) (Anglais)

Although EGF receptor is crucial for the normal cellular function, its expression clearly appears to contribute to the development of various cancers. Increased expression of EGFR is associated with enhanced tumor invasiveness and resistance to chemotherapy. We recently developed a new recombinant molecule named Peptabody anti EGFR which allows the targeting of these cancer cells and the subsequent induction of apoptosis. The purpose of this project is the optimization of Peptabody production and the identification of its potential indications in oncology.